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Background
Nitric oxide (NO) is an essential vasodilator. In vascular
diseases, oxidative stress attenuates NO signaling by both
chemical scavenging of free NO and oxidation and down-
regulation of its major intracellular receptor, the α/β het-
erodimeric heme-containing soluble guanylate cyclase
(sGC). Oxidation can also induce loss of sGC's heme and
responsiveness to NO.
Results
sGC activators such as BAY 58-2667 bind to oxidized/
heme-free sGC and reactivate the enzyme to exert disease-
specific vasodilation. Here we show that oxidation-
induced down-regulation of sGC protein extends to iso-
lated blood vessels. Mechanistically, degradation was trig-
gered through sGC ubiquitination and proteasomal
degradation. The heme-binding site ligand, BAY 58-2667,
prevented sGC ubiquitination and stabilized both α and
β subunits.
Conclusion
Collectively, our data establish oxidation-ubiquitination
of sGC as a modulator of NO/cGMP signaling and point
to a new mechanism of action for sGC activating vasodi-
lators by stabilizing their receptor, oxidized/heme-free
sGC.
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